A Wall Street firm says these 19 companies are set to dominate the broader market over the next year
Apple
Avalara
Ticker: AVLR
Rating: Buy
Price Target: $85
Why: Scott Bert, an analyst at Needham, said Avalara, which provides tax compliance software, will benefit from secular tailwinds and new partnerships opportunities with ecommerce marketplaces.
Source: Needham & Company
Boston Scientific
Ticker: BSX
Rating: Strong Buy
Price Target: $46
Why: "We think BSX has a strong product cycle that should allow it to outpace its peers," Mike Matson, an analyst at Needham said in the report.
Source: Needham & Company
Collegium Pharmaceutical
Ticker: COLL
Rating: Buy
Price Target: $33
Why: Collegium is currently trading an attractive valuation for investors to buy into the stock, and the the success of the company's Xtampza drug could help it reach profitability by the end of the year, according to Serge Belanger, an analyst at Needham said.
Source: Needham & Company
Coupa Software
Ticker: COUP
Rating: Buy
Price Target: $140
Why: Ryan MacDonald, an analyst at Needham, picked Coupa Software, which specializes in business spend management software, because he thinks the company can grow more 30% over the next few years.
Source: Needham & Company
Cubic
Ticker: CUB
Rating: Buy
Price Target: $77
Why: "CUB continues to add key new contract awards in all three of its operating segments, providing additional visibility into its near-record multi-billion-dollar backlog." Jim Ricchiuti, an analyst at Needham said.
Source: Needham & Company
Designer Brands
Ticker: DBI
Rating: Buy
Price Target: $32
Why: "We are placing Designer Brands on the Needham Conviction List, as we believe the business is poised to improve in 2H19 following lumpiness in 1H19, and is poised for an even better 2020," Rick Patel, an analyst at Needham said.
Source: Needham & Company
G1 Therapeutics
Ticker: GTHX
Rating: Buy
Price Target: $74
Why: Chad Messer, an analyst at Needham, said G1 Therapeutics's Trilaciclib, a myelopreservation drug, has a stronger chance of receiving regulatory approval.
Source: Needham & Company
Luckin Coffee
Ticker: LK
Rating: Buy
Price Target: $27
Why: "We believe in LK's profitability outlook as cost per item should reduce significantly owing to economics of scale, and the scale-down of promotions." Vincent Shenghao Yu, an analyst at Needham said.
Source: Needham & Company
Lumentum Holdings
Ticker: LITE
Rating: Strong Buy
Price Target: $62
Why: Lumentum, a manufacturer of telecommunications equipment, has the dominant technology in critical telecommunications markets, according to Alex Henderson, an analyst at Needham.
Source: Needham & Company
Marvell Technology Group
Ticker: MRVL
Rating: Buy
Price Target: $28
Why: "We believe MRVL represents one of the best semiconductor plays on the global deployment of 5G wireless infrastructure equipment," N. Quinn Bolton, an analyst at Needham said.
Source: Needham & Company
New Relic
Ticker: NEWR
Rating: Buy
Price Target: $131
Why: "NEWR is a provider of a full stack monitoring solution that allows enterprises to instrument and ensure continuous operability of mission-critical applications, which is becoming more important as enterprises expose more of their organizational facets to digital surfaces," Jack Andrews, an analyst at Needham said.
Source: Needham & Company
ON Semiconductor
Ticker: ON
Rating: Strong Buy
Price Target: $27
Why: Needham analyst Rajvindra Gill said ON Semiconductor's initiatives in 5G infrastructure and server power management look promising.
Source: Needham & Company
Rhythm Pharmaceuticals
Ticker: RYTM
Rating: Buy
Price Target: $42
Why: Alan Carr, an analyst at Needham, said Rhythm is developing a treatment for rare obesity disorders that could be approved and launched by the fourth quarter of 2020.
Source: Needham and Company
SS&C Technologies Holdings
Ticker: SS&C
Rating: Strong Buy
Price Target: $77
Why: "We are placing SS&C Technologies Holdings on the Needham Conviction List, given our belief that the company will be able to combine solid organic growth with acquisition synergies from the 2018 acquisitions of DST, Eze Software, and Intralinks to drive outsized EPS growth." Needham Analyst Mayank Tandon said in a research note.
Source: Needham & Company
TripAdvisor
Ticker: TRIP
Rating: Buy
Price Target: $63
Why: "We continue to think sponsored placements with the Hotel segment, in particular, carries ongoing tailwind potential as a part of Hotel, Media & Platform's return to growth," Brad Erickson, an analyst at Needham said in a research note.
Source: Needham & Company
Veracyte
Ticker: VCYT
Rating: Buy
Price Target: $33
Why: Stephen Unger, an analyst Needham, said he sees potential in for Veracyte to generate long-term revenue growth by commercializing its expanding portfolio of diagnostic tests.
Source: Needham & Company
Vonage
Ticker: VG
Rating: Buy
Price Target: $14
Why: According to Richard Valera, an analyst at Needham, Vonage is well-positioned to capitalize on a shift in the telecommunications market toward an IP/cloud-based paradigm.
Source: Needham & Company
Zscaler
Ticker: ZS
Rating: Strong Buy
Price Target: $89
Why: "We believe ZS is the first full cloud Security platform based on the core fundamental principles needed to build a better security architecture, sharply reduce breach risk, and ensure consistent security policy and scale," Alex Henderson, an analyst at Needham said.
Source: Needham & Company
Popular Right Now
Advertisement